Maxim Group Upgrades Galmed Pharmaceuticals (GLMD) to Buy
Tweet
Share
E-mailGet Alerts GLMD Hot Sheet
Price: $4.56 -4.4%
Rating Summary:
5 Buy, 6 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 15 | New: 40
Rating Summary:
5 Buy, 6 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 15 | New: 40
Join SI Premium – FREE
Maxim Group analyst Jason McCarthy upgraded Galmed Pharmaceuticals (NASDAQ: GLMD) from Hold to Buy with a price target of $4.00.
For an analyst ratings summary and ratings history on Galmed Pharmaceuticals click here. For more ratings news on Galmed Pharmaceuticals click here.
Shares of Galmed Pharmaceuticals closed at $1.15 yesterday.
You May Also Be Interested In
- Galmed's Colospan reports feasibility data on tissue assessment tool
- Deutsche Bank Upgrades Target Hospitality (TH) to Buy
- Northland Upgrades CIENA (CIEN) to Outperform
Create E-mail Alert Related Categories
Hot Upgrades, UpgradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
